Silver Book Fact

Stem Cell Therapy Study Shows Improved Motor Function in Parkinson’s

Fact image

Scheiss M, Suescun J, Ellmore T, et al. Preliminary Report on the Safety and Tolerability of Bone Marrow-Derived Allogenic Mesenchymal Stem Cells Infused Intravenously in Parkinson’s Disease Patients; 2019. https://n.neurology.org/content/92/15_Supplement/S16.008. Accessed June 11, 2019

Reference

Title
Preliminary Report on the Safety and Tolerability of Bone Marrow-Derived Allogenic Mesenchymal Stem Cells Infused Intravenously in Parkinson’s Disease Patients
Publication
Neurology
Publication Date
2019
Authors
Scheiss M, Suescun J, Ellmore T, et al
Volume & Issue
Volume 19, Issue 15S
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Some studies have indicate that the management of high cholesterol, type 2 diabetes, high blood pressure, overweight or obesity, and other cardiovascular risk factors may help avoid or delay cognitive…  
  • Impact of a 5-Year Delay in Onset on Costs, Americans Age 65 and Older with Alzhemier’s Disease, 2010-2050  
  • In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2…  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.  
  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.